Durvalumab addtion to chemo shows endometrial cancer benefit

Durvalumab & Olaparib As Maintenance In Patients With Mmr-proficient Advanced Endometrial Cancer

Immunotherapy In Endometrial Cancer: Expanding Horizons

Neoadjuvant Durvalumab Shows Benefit In Triple-negative Breast Cancer

A Study Of Chemotherapy With Durvalumab And Tremelimumab In Nsclc

Molecular Classification Of Endometrial Cancer And Targeted Therapy Considerations

Maximizing The Of Potential Current And Emerging Immunotherapies In Advanced Endometrial Cancer

Topaz-1: The Addition Of Durvalumab To Chemotherpay For The Treatment Of Btc In The 1st-line Setting

Durvalumab Plus Chemotherapy Significantly Improved Os In Advanced Biliary Tract Cancer

Poseidon: Durvalumab /- Tremelimumab Chemo In 1l Mnsclc

Four Chemo Cycles Given With Durvalumab ± Tremelimumab Optimise Response In Patients With Mnsclc

Calla: Phase Iii Study Of Durvalumab And Chemoradiotherapy For Cervical Cancer

Olaparib Durvalumab As A Chemotherapy-free Maintenance Strategy In Platinum Treated Advanced Tnbc

Durvalumab And Pet-directed Chemoradiation In Advanced Esophageal Cancer

Danube Trial: Durvalumab Alone Or With Tremelimumab For Metastatic Bladder Cancer

Durvalumab /- Tremelimumab Versus Chemotherapy For First-line Advanced Urothelial Carcinoma

Concurrent Low-dose Radiation And Durvalumab And Etoposide/platinum Shows Promising Efficacy In ...

Durvalumab With Olapirib Shows No Pfs Improvement For Platinum-ineligible Bladder Cancer

Immunotherapy As A Treatment Cornerstone For Advanced Endometrial Cancer

Imfinzi® (durvalumab) Plus Chemotherapy Approved In The Us As The First Immunotherapy Regimen...